300016 北陆药业
已收盘 07-19 15:00:00
资讯
新帖
简况
【机构调研记录】淳厚基金调研北陆药业、物产金轮等5只个股(附名单)
证券之星 · 07-18 08:01
【机构调研记录】淳厚基金调研北陆药业、物产金轮等5只个股(附名单)
【机构调研记录】中邮基金调研北陆药业
证券之星 · 07-18 08:01
【机构调研记录】中邮基金调研北陆药业
北陆药业最新公告:获得钆特酸葡胺注射液《药品注册证书》
证券之星 · 07-05
北陆药业最新公告:获得钆特酸葡胺注射液《药品注册证书》
北陆药业(300016.SZ)获钆特酸葡胺注射液药品注册证书
智通财经网 · 07-05
北陆药业(300016.SZ)获钆特酸葡胺注射液药品注册证书
【机构调研记录】中航基金调研万通发展、北陆药业等3只个股(附名单)
证券之星 · 07-04
【机构调研记录】中航基金调研万通发展、北陆药业等3只个股(附名单)
北陆药业接待20家机构调研,包括国盛证券、中信建投、正圆投资等
金融界 · 07-03
北陆药业接待20家机构调研,包括国盛证券、中信建投、正圆投资等
北陆药业(300016.SZ):钆特酸葡胺化学原料药获批上市
智通财经网 · 07-01
北陆药业(300016.SZ):钆特酸葡胺化学原料药获批上市
北陆药业:天原药业目前产能充足,暂不需要提升产能
证券之星 · 06-24
北陆药业:天原药业目前产能充足,暂不需要提升产能
北陆药业:公司历年年度报告中均详细说明了公司当年的经营情况及对未来的规划,敬请查阅巨潮资讯网
证券之星 · 06-14
北陆药业:公司历年年度报告中均详细说明了公司当年的经营情况及对未来的规划,敬请查阅巨潮资讯网
北陆药业最新公告:完成收购承德天原药业80%股权
证券之星 · 06-07
北陆药业最新公告:完成收购承德天原药业80%股权
北陆药业:公司收购天原药业80%股权完成后,将多一个生产基地
证券之星 · 06-06
北陆药业:公司收购天原药业80%股权完成后,将多一个生产基地
北陆药业新提交1件商标注册申请
证券之星 · 06-06
北陆药业新提交1件商标注册申请
北陆药业:新口味九味镇心颗粒完成相应药监部门的批准后将上市销售,公司会按照信披要求及时披露,敬请关注
证券之星 · 06-03
北陆药业:新口味九味镇心颗粒完成相应药监部门的批准后将上市销售,公司会按照信披要求及时披露,敬请关注
北陆药业:公司一季度毛利率增长主要系产品销售结构的变化导致
证券之星 · 05-15
北陆药业:公司一季度毛利率增长主要系产品销售结构的变化导致
北陆药业:公司产品未涉及生物合成技术
证券之星 · 05-10
北陆药业:公司产品未涉及生物合成技术
北陆药业(300016.SZ)收到盐酸帕罗西汀肠溶缓释片药品注册证书
智通财经 · 05-09
北陆药业(300016.SZ)收到盐酸帕罗西汀肠溶缓释片药品注册证书
【机构调研记录】民生加银基金调研电连技术、北陆药业等7只个股(附名单)
证券之星 · 04-26
【机构调研记录】民生加银基金调研电连技术、北陆药业等7只个股(附名单)
北陆药业:华安证券、山西证券等多家机构于4月24日调研我司
证券之星 · 04-25
北陆药业:华安证券、山西证券等多家机构于4月24日调研我司
北陆药业:兴全基金、永赢基金等多家机构于4月23日调研我司
证券之星 · 04-24
北陆药业:兴全基金、永赢基金等多家机构于4月23日调研我司
北陆药业新提交“北陆药业”商标注册申请
证券之星 · 04-24
北陆药业新提交“北陆药业”商标注册申请
加载更多
公司概况
公司名称:
北京北陆药业股份有限公司
所属行业:
医药制造业
上市日期:
2009-10-30
主营业务:
北京北陆药业股份有限公司的主营业务为对比剂制剂及原料药、中枢神经类和降糖类药品的研发、生产与销售。公司的主要产品为钆喷酸葡胺注射液、钆布醇注射液、钆贝葡胺注射液、碘海醇注射液、碘帕醇注射液、碘克沙醇注射液、格列美脲片、瑞格列奈片、九味镇心颗粒、钆喷酸葡胺及辅料、钆布醇及辅料、碘海醇、碘佛醇、碘克沙醇、碘普罗胺及碘帕醇。公司是我国对比剂行业的市场领先者。
发行价格:
17.86
{"stockData":{"symbol":"300016","market":"SZ","secType":"STK","nameCN":"北陆药业","latestPrice":4.39,"timestamp":1721372622000,"preClose":4.39,"halted":0,"volume":3370111,"delay":0,"floatShares":491000000,"shares":492000000,"eps":-0.1481,"marketStatus":"已收盘","marketStatusCode":5,"change":0,"latestTime":"07-19 15:00:00","open":4.35,"high":4.41,"low":4.29,"amount":14690000,"amplitude":0.0273,"askPrice":4.39,"askSize":932,"bidPrice":4.38,"bidSize":105,"shortable":0,"etf":0,"ttmEps":-0.1481,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721611800000},"adr":0,"adjPreClose":4.39,"symbolType":"stock","openAndCloseTimeList":[[1721352600000,1721359800000],[1721365200000,1721372400000]],"highLimit":4.83,"lowLimit":3.95,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":491935176,"pbRate":1.39,"roa":"--","roe":"0.7%","epsLYR":-0.15,"committee":-0.489154,"marketValue":2160000000,"floatMarketCap":2156000000,"peRate":-29.642133,"changeRate":0,"turnoverRate":0.0069,"status":2},"requestUrl":"/m/hq/s/300016","defaultTab":"news","newsList":[{"id":"2452111476","title":"【机构调研记录】淳厚基金调研北陆药业、物产金轮等5只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2452111476","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452111476?lang=zh_cn&edition=full","pubTime":"2024-07-18 08:01","pubTimestamp":1721260915,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及7月17日披露的机构调研信息,淳厚基金近期对5家上市公司进行了调研,相关名单如下:1)北陆药业 (淳厚基金参与公司特定对象调研)个股亮点:北陆转债(123082)于2020-12-28上市;公司已联合平安好医生、好心情互联网医院推出疫情期间的免费心理义诊活动;参股公司医未医疗作为要盖全脑诊疗全流程的脑科学数字产品公司2)物产金轮 (淳厚基金管理有限公司参与公司腾讯会","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071800012780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0046","BK0145","BK0256","BK0077","300016","BK0060","BK0239","002722","BK0028","BK0070"],"gpt_icon":0},{"id":"2452114763","title":"【机构调研记录】中邮基金调研北陆药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2452114763","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452114763?lang=zh_cn&edition=full","pubTime":"2024-07-18 08:01","pubTimestamp":1721260869,"startTime":"0","endTime":"0","summary":"旗下最近一年表现最佳的公募基金产品为中邮纯债裕利三个月定开债,最新单位净值为1.03,近一年增长9.06%。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071800012700.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300016","BK0042","BK0060"],"gpt_icon":0},{"id":"2449507532","title":"北陆药业最新公告:获得钆特酸葡胺注射液《药品注册证书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2449507532","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449507532?lang=zh_cn&edition=full","pubTime":"2024-07-05 18:40","pubTimestamp":1720176033,"startTime":"0","endTime":"0","summary":"北陆药业公告,近日收到国家药品监督管理局核准签发的钆特酸葡胺注射液《药品注册证书》。钆特酸葡胺注射液是一种用于磁共振成像(MRI)的静脉注射造影剂。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070500039245.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300016","BK0046","BK0060","BK0042","BK0239"],"gpt_icon":0},{"id":"2449257077","title":"北陆药业(300016.SZ)获钆特酸葡胺注射液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2449257077","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449257077?lang=zh_cn&edition=full","pubTime":"2024-07-05 18:29","pubTimestamp":1720175379,"startTime":"0","endTime":"0","summary":"北陆药业(300016.SZ)公告,公司收到国家药品监督管理局核准签发的钆特酸葡胺...","market":"sg","thumbnail":"https://img.zhitongcaijing.com/astock/16.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/16.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1146293.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["300016","BK0046","BK0060","BK0042","BK0239"],"gpt_icon":0},{"id":"2448454212","title":"【机构调研记录】中航基金调研万通发展、北陆药业等3只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2448454212","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448454212?lang=zh_cn&edition=full","pubTime":"2024-07-04 08:01","pubTimestamp":1720051277,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及7月3日披露的机构调研信息,中航基金近期对3家上市公司进行了调研,相关名单如下:1)万通发展 个股亮点:公司将稀布相控阵技术与5G毫米波相控阵芯片及低轨卫星终端相控阵芯片的专业化设计能力结合起来,支撑5G毫米波相控阵T/R芯片国产化。旗下最近一年表现最佳的公募基金产品为中航瑞发3个月定开债A,最新单位净值为1.02,近一年增长5.39%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407040803079eff492c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407040803079eff492c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0172","BK0239","BK0042","600246","BK0060","BK0046","BK0273","BK0088","300016"],"gpt_icon":0},{"id":"2448177698","title":"北陆药业接待20家机构调研,包括国盛证券、中信建投、正圆投资等","url":"https://stock-news.laohu8.com/highlight/detail?id=2448177698","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448177698?lang=zh_cn&edition=full","pubTime":"2024-07-03 17:41","pubTimestamp":1719999678,"startTime":"0","endTime":"0","summary":"2024年7月3日,北陆药业披露接待调研公告,公司于7月3日接待国盛证券、中信建投、正圆投资、中航基金、博时基金等20家机构调研。公告显示,北陆药业参与本次接待的人员共1人,为董事会秘书邵泽慧。据了解,北陆药业对天原药业的收购已经完成,天原药业成为其控股子公司。针对化药端及中药端原材料价格波动,北陆药业采取了多项应对策略。北陆药业在中成药领域的重要战略布局是位于安徽省亳州市的生产基地。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407031756419efb1213&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407031756419efb1213&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0046","161027","06066","601066","BK0042","BK0239","BK0060","300016","BK0276"],"gpt_icon":0},{"id":"2448964210","title":"北陆药业(300016.SZ):钆特酸葡胺化学原料药获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2448964210","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448964210?lang=zh_cn&edition=full","pubTime":"2024-07-01 17:46","pubTimestamp":1719827183,"startTime":"0","endTime":"0","summary":"智通财经APP讯,北陆药业(300016.SZ)公告,公司收到国家药品监督管理局核准签发的钆特酸葡胺化学原料药上市申请批准通知书。钆特酸葡胺化学原料药可用于生产钆特酸葡胺注射液,钆特酸葡胺注射液是一种用于磁共振成像(MRI)的静脉注射造影剂。更多港股重磅资讯,下载智通财经app更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1143646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0042","BK0239","BK0046","BK0060","300016"],"gpt_icon":0},{"id":"2445728028","title":"北陆药业:天原药业目前产能充足,暂不需要提升产能","url":"https://stock-news.laohu8.com/highlight/detail?id=2445728028","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445728028?lang=zh_cn&edition=full","pubTime":"2024-06-24 17:04","pubTimestamp":1719219859,"startTime":"0","endTime":"0","summary":"证券之星消息,北陆药业06月24日在投资者关系平台上答复投资者关心的问题。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062400024099.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300016","BK0042","BK0046"],"gpt_icon":0},{"id":"2443647871","title":"北陆药业:公司历年年度报告中均详细说明了公司当年的经营情况及对未来的规划,敬请查阅巨潮资讯网","url":"https://stock-news.laohu8.com/highlight/detail?id=2443647871","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443647871?lang=zh_cn&edition=full","pubTime":"2024-06-14 18:04","pubTimestamp":1718359459,"startTime":"0","endTime":"0","summary":"证券之星消息,北陆药业06月14日在投资者关系平台上答复投资者关心的问题。公司历年年度报告中均详细说明了公司当年的经营情况及对未来的规划,敬请查阅巨潮资讯网。投资者:请问董秘,公司参股的世和基因于今年4月份撤回了IPO申请,公司持股的世和基因股权估值是否需要调整?公司目前将持有的世和基因股权在其他非流动金融资产列报,以公允价值进行计量,公司无获得世和基因控股权的意向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061400036498.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0060","BK0042","300016","BK0239"],"gpt_icon":0},{"id":"2441758031","title":"北陆药业最新公告:完成收购承德天原药业80%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2441758031","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441758031?lang=zh_cn&edition=full","pubTime":"2024-06-07 16:32","pubTimestamp":1717749154,"startTime":"0","endTime":"0","summary":"北陆药业公告,截至公告日,公司根据《关于承德天原药业有限公司的股权转让协议》相关约定,已完成了管理权交接等工作,并向金安国纪集团股份有限公司支付完毕本次交易的全部转让对价,公司收购承德天原药业有限公司80%股权的事项已完成。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060700030438.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0042","BK0239","BK0060","300016"],"gpt_icon":0},{"id":"2441692791","title":"北陆药业:公司收购天原药业80%股权完成后,将多一个生产基地","url":"https://stock-news.laohu8.com/highlight/detail?id=2441692791","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441692791?lang=zh_cn&edition=full","pubTime":"2024-06-06 18:04","pubTimestamp":1717668266,"startTime":"0","endTime":"0","summary":"证券之星消息,北陆药业06月06日在投资者关系平台上答复投资者关心的问题。公司收购天原药业80%股权完成后,将多一个生产基地。目前公司有三个生产基地负责生产,分别是密云药厂、海昌药业、沧州分公司, 同时在有序推进位于安徽省亳州市的第四生产基地的建设工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060600036879.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300016","BK0042","BK0046","BK0060"],"gpt_icon":0},{"id":"2441765467","title":"北陆药业新提交1件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2441765467","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441765467?lang=zh_cn&edition=full","pubTime":"2024-06-06 14:46","pubTimestamp":1717656368,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示,近日北京北陆药业股份有限公司新提交1件商标注册申请。商标申请详情如下:今年以来北京北陆药业股份有限公司新申请注册商标3件,截止目前公司共持有注册商标110件,另有26件商标尚在注册申请中。数据来源:企查查以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060600024018.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300016","BK0042","BK0046","BK0060"],"gpt_icon":0},{"id":"2440452329","title":"北陆药业:新口味九味镇心颗粒完成相应药监部门的批准后将上市销售,公司会按照信披要求及时披露,敬请关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2440452329","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440452329?lang=zh_cn&edition=full","pubTime":"2024-06-03 17:06","pubTimestamp":1717405587,"startTime":"0","endTime":"0","summary":"投资者:请问贵公司九味镇心颗粒2015~2018年营业成本分别是多少啊,年报中未披露。公司收购天原药业尚未全部完成,本次交易完成后,天原药业将纳入公司合并报表范围内,关于金莲花产品的经营情况敬请关注公司后续披露的定期报告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060300021413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300016","BK0046","BK0060","BK0042","BK0239"],"gpt_icon":0},{"id":"2435680218","title":"北陆药业:公司一季度毛利率增长主要系产品销售结构的变化导致","url":"https://stock-news.laohu8.com/highlight/detail?id=2435680218","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435680218?lang=zh_cn&edition=full","pubTime":"2024-05-15 18:03","pubTimestamp":1715767385,"startTime":"0","endTime":"0","summary":"证券之星消息,北陆药业05月15日在投资者关系平台上答复投资者关心的问题。公司年报数据积极向好,看到在研项目中有多个维生素项目~。随着项目的研发及申报进度,我们将逐步披露维生素项目的相关信息,敬请关注。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051500030924.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300016","BK0042","BK0046"],"gpt_icon":0},{"id":"2434367658","title":"北陆药业:公司产品未涉及生物合成技术","url":"https://stock-news.laohu8.com/highlight/detail?id=2434367658","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434367658?lang=zh_cn&edition=full","pubTime":"2024-05-10 18:03","pubTimestamp":1715335439,"startTime":"0","endTime":"0","summary":"证券之星消息,北陆药业05月10日在投资者关系平台上答复投资者关心的问题。参股公司世和基因、芝友医疗及医未医疗主营业务分别涉及高通量基因测序、药物基因组及肿瘤靶向用药的分子诊断试剂、脑科学及AI辅助诊断等,其他业务情况请参见各公司官网及微信公众号。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051000035939.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300016","BK0239","BK0042","BK0046"],"gpt_icon":0},{"id":"2434851064","title":"北陆药业(300016.SZ)收到盐酸帕罗西汀肠溶缓释片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2434851064","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434851064?lang=zh_cn&edition=full","pubTime":"2024-05-09 17:57","pubTimestamp":1715248620,"startTime":"0","endTime":"0","summary":"智通财经APP讯,北陆药业(300016.SZ)公告,公司收到国家药品监督管理局核准签发的盐酸帕罗西汀肠溶缓释片《药品注册证书》。公告显示,“盐酸帕罗西汀肠溶缓释片”用于治疗成人抑郁症,国家医保目录乙类,由葛兰素史克研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1119348.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0042","300016","BK0060","BK0239","BK0046"],"gpt_icon":0},{"id":"2430261171","title":"【机构调研记录】民生加银基金调研电连技术、北陆药业等7只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2430261171","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430261171?lang=zh_cn&edition=full","pubTime":"2024-04-26 08:02","pubTimestamp":1714089778,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及4月25日披露的机构调研信息,民生加银基金近期对7家上市公司进行了调研,相关名单如下:1)电连技术 个股亮点:公司对英伟达有公司相关产品的研发送样;公司表示小米公司是公司的重要客户。民生加银基金成立于2008年,截至目前,资产管理规模1474.6亿元,排名40/203;资产管理规模1226.63亿元,排名36/203;管理公募基金数157只,排名40/203;旗下公募基金经理29人,排名42/203。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600016038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0214","300016","BK0060","300679","BK0042"],"gpt_icon":0},{"id":"2430478689","title":"北陆药业:华安证券、山西证券等多家机构于4月24日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2430478689","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430478689?lang=zh_cn&edition=full","pubTime":"2024-04-25 16:34","pubTimestamp":1714034065,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年4月25日北陆药业发布公告称华安证券谭国超 谢涛 刘洪飞、山西证券王腾蛟、韫然资管徐康、东财基金王陈怡、广发基金吴晓钢、创钰资管唐小皓、宁波知远资管刘永刚、德瑞恒泰基金赵一帆、民生加银基金李由、华宝基金杜舟 张金涛、天治基金王娟、安联投资张祝源、太平基金闫庚威、东方红徐宏于2024年4月24日调研我司。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500033301.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","BK0188","BK0183","BK0201","002500","BK0042","BK0046","BK0276","600909","BK0028","300016"],"gpt_icon":0},{"id":"2429433765","title":"北陆药业:兴全基金、永赢基金等多家机构于4月23日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2429433765","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429433765?lang=zh_cn&edition=full","pubTime":"2024-04-24 18:15","pubTimestamp":1713953713,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年4月24日北陆药业发布公告称兴全基金朱喆丰 厉之千 丁小晨、永赢基金陆凯琳于2024年4月23日调研我司。北陆药业2024年一季报显示,公司主营收入2.08亿元,同比上升10.35%;归母净利润1152.62万元,同比下降8.35%;扣非净利润1144.64万元,同比上升32.95%;负债率37.3%,投资收益84.98万元,财务费用1271.93万元,毛利率55.61%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400038237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","300016","BK0060","BK0239","BK0046"],"gpt_icon":0},{"id":"2429510912","title":"北陆药业新提交“北陆药业”商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2429510912","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429510912?lang=zh_cn&edition=full","pubTime":"2024-04-24 13:36","pubTimestamp":1713936969,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示,近日北京北陆药业股份有限公司新提交“北陆药业”商标注册申请。商标申请详情如下:今年以来北京北陆药业股份有限公司新申请注册商标2件,截止目前公司共持有注册商标110件,另有25件商标尚在注册申请中。数据来源:企查查以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400024544.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","300016","BK0060","BK0239","BK0046"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2009-10-30","address":"北京市密云区水源西路3号","stockEarnings":[{"period":"1week","weight":-0.0266},{"period":"1month","weight":-0.0288},{"period":"3month","weight":0.0305},{"period":"6month","weight":-0.3183},{"period":"1year","weight":-0.3257},{"period":"ytd","weight":-0.3834}],"companyName":"北京北陆药业股份有限公司","boardCode":"AI0027","perCapita":"16315股","boardName":"医药制造业","registeredCapital":"49193万元","compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0118},{"period":"3month","weight":-0.0271},{"period":"6month","weight":0.053},{"period":"1year","weight":-0.0591},{"period":"ytd","weight":0.0025}],"survey":" 北京北陆药业股份有限公司的主营业务为对比剂制剂及原料药、中枢神经类和降糖类药品的研发、生产与销售。公司的主要产品为钆喷酸葡胺注射液、钆布醇注射液、钆贝葡胺注射液、碘海醇注射液、碘帕醇注射液、碘克沙醇注射液、格列美脲片、瑞格列奈片、九味镇心颗粒、钆喷酸葡胺及辅料、钆布醇及辅料、碘海醇、碘佛醇、碘克沙醇、碘普罗胺及碘帕醇。公司是我国对比剂行业的市场领先者。","serverTime":1721471006770,"listedPrice":17.86,"stockholders":"30105人(较上一季度增加0.95%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"北陆药业(300016)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供北陆药业(300016)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"北陆药业,300016,北陆药业股票,北陆药业股票老虎,北陆药业股票老虎国际,北陆药业行情,北陆药业股票行情,北陆药业股价,北陆药业股市,北陆药业股票价格,北陆药业股票交易,北陆药业股票购买,北陆药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"北陆药业(300016)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供北陆药业(300016)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}